Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Syncona Limited
  6. News
  7. Summary
    BACT   GG00B8P59C08

SYNCONA LIMITED

(BACT)
  Report
Real-time Estimate Cboe Europe  -  03:32:12 2023-02-07 am EST
177.80 GBX   -1.22%
02:36aSyncona's Fiscal Q3 Net Assets Decline
MT
02/06UK earnings, trading statements calendar - next 7 days
AN
01/25Life Science REIT lets second floor of Rolling Stock Yard in London
AN
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Syncona Extends Offer Period For $24 Million Takeover of Applied Genetic Technologies

11/29/2022 | 02:41am EST
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
SYNCONA LIMITED -1.48% 177.34 Delayed Quote.-0.55%
All news about SYNCONA LIMITED
02:36aSyncona's Fiscal Q3 Net Assets Decline
MT
02/06UK earnings, trading statements calendar - next 7 days
AN
01/25Life Science REIT lets second floor of Rolling Stock Yard in London
AN
2022Syncona's Autolus Raises Further $14 Million Via Add-On American Depositary Share Subsc..
MT
2022Syncona : SwanBio Therapeutics Initiates First-in-Human Study of AAV Gene Therapy for Adre..
PU
2022Syncona Unit's Mid-Stage Study for Blood Cancer Drug Meets Primary Endpoint
MT
2022Syncona to Secure 18.5% Stake in Autolus Therapeutics
MT
2022Syncona portfolio firm hits 70% remission rate goal in leukaemia trial
AN
2022Syncona Portfolio Shares Inch Up on Portfolio Company's Cancer Treatment Update
MT
2022Syncona investee Achilles continues to progress cancer trials
AN
More news
Financials
Sales 2023 - - -
Net income 2023 - - -
Net cash 2023 663 M 797 M 797 M
P/E ratio 2023 -
Yield 2023 -
Capitalization 1 205 M 1 448 M 1 448 M
EV / Sales 2023 -
Capi. / Sales 2024 -
Nbr of Employees 1 180
Free-Float 97,7%
Chart SYNCONA LIMITED
Duration : Period :
Syncona Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SYNCONA LIMITED
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 180,00 GBX
Average target price 242,50 GBX
Spread / Average Target 34,7%
Managers and Directors
Martin Patrick Murphy Chief Executive Officer
Rolf Kristian Soderstrom Chief Financial Officer
Melanie Gee Chairman
Markus John Chief Medical Officer, Head-Research & Development
Christopher John Hollowood Chief Investment Officer
Sector and Competitors
1st jan.Capi. (M$)
SYNCONA LIMITED-0.55%1 448
INVESTOR AB (PUBL)11.01%61 870
CK HUTCHISON HOLDINGS LIMITED5.23%24 067
GROUPE BRUXELLES LAMBERT SA6.84%12 509
HAL TRUST3.67%12 248
KOÇ HOLDING A.S.-8.60%10 417